Testing a combination treatment for gastric cancer with limited spread

Plain-English translation of NCT06091423 on ClinicalTrials.gov ↗ · Source last updated November 2023 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination treatment using XELOX, fruquintinib, and sintilimab for people with gastric cancer or gastroesophageal junction cancer that has spread to the liver and/or nearby lymph nodes in the back of the abdomen. The goal is to give you this medication combination before surgery to shrink the cancer as much as possible, making it easier for surgeons to remove it completely.

Most people with gastric cancer that has spread cannot be cured by surgery alone. This trial exists to see whether treating patients with this medication combination first can shrink the cancer enough that more patients become candidates for successful surgery, potentially improving survival and quality of life.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with gastric or esophageal junction cancer that has spread only to the liver and/or retroperitoneal lymph nodes (5 or fewer spots, each smaller than 5 centimeters)
your cancer has not been previously treated with similar medications (VEGFR-targeted drugs or PD-1/PD-L1 inhibitors)
your doctor considers your primary tumor and nearby lymph nodes potentially removable by surgery
you are in good overall health with adequate organ function (normal blood counts, liver and kidney function, heart function)

You likely don't qualify if…

you have cancer that has spread to other sites like the lungs, brain, bones, or abdominal lining
you have a history of serious bleeding or had a bleeding event in the last 4 weeks
you have uncontrolled high blood pressure or a history of unstable heart problems
you cannot take oral medications due to swallowing difficulties, severe diarrhea, or bowel obstruction
you have participated in another drug trial within the last 4 weeks

What participation looks like

You would receive the medication combination intravenously and by mouth over 4 to 6 treatment cycles (typically several weeks apart). During this time, your doctors will monitor how well the treatment is working with imaging scans and blood tests. If the cancer shrinks enough, you would then have surgery or other procedures to remove the remaining tumors. You'll have regular follow-up visits to watch for side effects and track your progress.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Testing a combination treatment for gastric cancer with limited spread

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)